USPTO Examiner Affirms Rejection of Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has issued a Reexamination Advisory Action regarding the relevant claims of the ‘483 patent that Magnolia Medical asserted against the Kurin Lock product. The Patent Office found that Magnolia’s arguments regarding claims 1 and 24 do not overcome its prior final rejection of these claims, and noted that any finally rejected claims will be cancelled.

“We are pleased to see yet another affirmation that we are on the right side of this legal process,” said Bob Rogers, CEO of Kurin, Inc. “The Advisory Action is unambiguous and offers great detail on why the arguments presented by Magnolia fail to overcome the USPTO’s determination that these claims are not valid, providing great clarity on this legal matter.”

“Magnolia Medical continues to abuse the legal system and the patent continuation process in an attempt to use the Courts and USPTO to do what it cannot do in the marketplace. We will continue to vigorously defend our rights. Kurin is the market leader in this space due to the ease-of-use of the Kurin product line, and continues to grow at a fast pace with further innovations being developed.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at